The latest pundit take on the stock provided a good reason for bulls to snap it up.
Investors took profits a day after the clinical-stage biotech company's shares soared.
Breakthrough Results from Study C602 Soleno Therapeutics, Inc. (NASDAQ: SLNO), a trailblazer in the biopharmaceutical industry, recently unveiled its promising
Soleno announced positive top-line results for DCCR, its lead therapy.
Soleno Therapeutics, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.
March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices closed lower for a fourth straight session, with Nasdaq dropping the most as market participants'...
Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.
Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.
KemPharm (KMPH) reports positive top line from a study evaluating serdexmethylphenidate (SDX) for cardiovascular safety to progress the development of its prodrug KP1077.